Press

Cybin Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Jun 24 • 4 min read

Cybin Inc. (NYSE :CYBN | NEO:CYBN), a biopharmaceutical company focused on progressing ‘Psychedelics to TherapeuticsTM’, reported audited financial results for its fiscal year ended March 31, 2022 and recent business highlights. The Company also reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. ‘Cybin made important progress across the board in recent months, accelerating both our…

Silo Pharma Expands License Agreement and Patent Portfolio

Jun 23 • 2 min read

Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a therapeutic, today announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting autoimmune diseases. “We are delighted to expand our partnership…

Numinus Applies for International Patent Filing of Psychedelics Production Process

Jun 22 • 2 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. has filed a patent application to the World Intellectual Property Organization (WIPO), an agency of the United Nations, for a rapid production process for Psilocybe and…

Why Choose Ibogaine for Healing?: Mindshifting Moments – Stream #2

Jun 21 • 1 min read

Many people use our Neuly psychedelic database and platform to research the many psychedelic compounds that are receiving press and buzz. Of course, there are some that are more popular than others. But what people may overlook, may be the right fit for them. After all, there is a myriad of benefits spanning all available…

Lobe Sciences and Clearway Global Enter into Agreement to Manage Lobe Science’s Global Regulatory and Development Strategy and Implementation

Jun 21 • 3 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBED), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC. “We are pleased to have the opportunity to team up with the Clearway network and in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435